






Future of Digital Health

Recai Serdar Gemici, Albert Health


Shift from wellness to chronic disease management



AI Articles in Literature



Evidence Studies in Digital Health




Source: IQVIA AppScript Clinical Evidence Database, August 14 2017


Report: The Growing Value of Digital Health. IQVIA Institute for Human Data Science, Nov 2017



Software as a Medical Device



Digital Therapeutics-DTx



About Us : Albert Health

3
Languages

150.000+
Registered users

40.000+
Active users

\$1.5M
Total Funding

techstars

wayra

SABANCI
VENTURES

Albert Health, November 2023



NHS

Abbott

GILEAD

BAYER

Pfizer

IQVIA™




Roche

AMGEN

sanofi


Multi-condition integrated care pathways

Designed by doctors



Available Device Integrations

Enable device connections to keep track of measurements



Easily connect to the assisted devices

Albert Health, November 2023



Accu-Chek Glucometer



Blood Pressure Monitor



Mi Health, Mi Body & Mi Band



Apple Health, IOS Devices & Wearables



Google Fit, Android Devices & Wearables






Thank you

serdar.gemici@albert.health

Evidence-based Multi-Chronic Disease Management Platform




**AI-based
Personalized Coach:
Albert**




Example Screens


Easy to Configure According to the Needs of the Disease




Special reminders




Albert medication adherence features



Disease-specific content (e.g. videos, supportive documents)



Special HCP list for telehealth



Disease-specific language model



Unique Journeys with Personalized Coaching

Increased patient engagement and improved clinical outcomes

Unique

Define sub patient groups, and create unique journeys according to the needs and priorities of patients.


Richard



Male, 31

Type-1 Diabetes & Allergy

Mary



Female, 49

Type-2 Diabetes & Obesity

Personalized

Send personalized notifications, reminders and refine journeys according to patient behaviors.



Gamified

Create checkpoints and assist your patient groups with pre-scheduled notifications.



Effortless

Provide right content at the right time whether it is a video or an informative document.



Agenda

- 1 Meet Albert Health
- 2 Future of Digital Health**
- 3 Digital Innovations of Today



Agenda

- 1 Meet Albert Health
- 2 Future of Digital Health
- 3 Digital Innovations of Today**



Examples

IDX-DR

FDA NEWS RELEASE

FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems

[f Share](#) [t Tweet](#) [in LinkedIn](#) [✉ Email](#) [🖨 Print](#)

For Immediate Release: April 11, 2018

[Español](#)

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.




Examples

ChestLink - Oxipit

First autonomous X-ray-analyzing AI is cleared in the EU

The AI imaging tool reads chest X-rays without the involvement of a radiologist

By [Nicole Wetsman](#) | Apr 5, 2022, 11:58am EDT




Powered by Voice

Reach patients from all ages and socioeconomical levels



Voiced notifications



Disease-specific language model



Pipeline – R&D Phase

1

Vocal Biomarker

Investigating the association of voice signal analysis with collected samples from patients in different clinical stages of heart failure.

2

Voice Assistant for HCPs

Helping clinicians take notes during and after operations just by talking with Albert.



AI-based Disease Management with Phone Call

- ✓ Call Center Integration
- ✓ Remote Patient Monitoring Solution



Uzaktan Saęlık Hizmetleri

Saęlık Bakanlıęı USBS gereksinimleri kapsamındaki temel özellikler




Uzaktan Saęlık
Bilgi Sistemi


- ✓ E-nabız Entegrasyonu
- ✓ E-reçete Entegrasyonu
- ✓ E-rapor Entegrasyonu
- ✓ Detaylı Tanı Giriş Ekranı
- ✓ Doktor Bilgi Bankası Entegrasyonu ile Hekim Doğrulama
- ✓ Onaylı Kullanıcı Arayüzü ve Kullanıcı Deneyimi Tasarımı
- ✓ Randevu öncesi uyarı mesajları, kamera&mikrofon izni uyarı ekranları



Our Vision




Transforming from a digital health company to a digital therapeutics company



Evidence-based Disease-specific Programs

Live in 4-6 weeks via Albert Mobile App


- ✓ Ready-to-use Digital Health Services
- ✓ Already trained language model in healthcare



Disease-specific
Parameters & Reminders


Disease-specific
Language Model Training

Live
via Albert Mobile App




Example Screens


Easy to Configure According to Needs of the Disease



Special reminders




Albert medication adherence features



Disease-specific content (e.g. videos, supportive documents)



Special HCP list for telehealth



Disease-specific language model


AI-based Personalized Coaching

Retain patient in the funnel

Richard



Male, 31
Obese



Pre-Scheduled

Create checkpoints and assist your user groups with pre-scheduled notifications.

Day 4

Day 9

Mary



Female, 49
Obese and Diabetic



Tailored

Create a journey for your each user group from day one and reach higher user engagement rates effortlessly.



We are Fully Vetted!

Trusted Partner of All Stakeholders



Secured

Information security as per ISO 27001 & ISO 27701



Validated

Software life cycle requirements as per IEC 62304



Qualified

Software quality as per ISO 15504 SPICE



Registered

Approved telehealth provider and enrolled to Turkish MoH




Interoperable


Compliant with DTAC and NHS standards (country based infrastructure)



Our vision: Digital Therapeutics



Transforming from a digital health company to a digital therapeutics company



Albert's Digital Therapeutics Pipeline

PRODUCT /CANDIDATE	INDICATION /TA	RESEARCH	DESIGN	POC	CLINICAL TRIAL	REGULATORY	PARTNER & SPONSOR
AH-001	MSK	[Progress bar: Research, Design, POC]			[Progress bar: Clinical Trial]	[Progress bar: Regulatory]	Acibadem University
AH-002	Heart Failure	[Progress bar: Research, Design, POC]			[Progress bar: Clinical Trial]	[Progress bar: Regulatory]	Dokuz Eylul University
AH-003	Asthma	[Progress bar: Research, Design]		[Progress bar: POC]	[Progress bar: Clinical Trial]	[Progress bar: Regulatory]	
AH-004	Multiple Sclerosis	[Progress bar: Research, Design]		[Progress bar: POC]	[Progress bar: Clinical Trial]	[Progress bar: Regulatory]	Roche, MS Society
AH-005	Hypertension	[Progress bar: Research, Design]		[Progress bar: POC]	[Progress bar: Clinical Trial]	[Progress bar: Regulatory]	Sanofi, Association of Hypertension Control
AH-006	Enteral Nutrition	[Progress bar: Research]	[Progress bar: Design]	[Progress bar: POC]	[Progress bar: Clinical Trial]	[Progress bar: Regulatory]	NHS Royal Wolverhampton Trust



Pipeline – R&D Phase

1

Vocal Biomarker

Investigating the association of voice signal analysis with collected samples from patients in different clinical stages of heart failure.

2

Clinical Trials

A clinical study that will investigate the in-person treatment versus remote treatment in the post-op phase by using Albert as a tool for patient reported outcomes.

3

Voice Assistant for HCPs

Helping clinicians take notes during and after operations just by talking with Albert.

4

Asthma

A mobile medical application to educate and empower patients to manage their asthma better.



Evidence Generation Throughout the Patient Journey

Generating Medical Value & Evidence

Data Collection

- Patient Reported Outcomes
- Health-related quality of life (HQRL, SF-12, etc.)
- Obesity symptoms and symptom burden
- Health behaviours (Diet, Medication use, Tobacco use, etc.)
- Health parameters (Blood pressure, Glucose level, HbA1c, etc.)
- Patient experience (App Analytics)
- NPS (Net Promoter Score)

Data Analysis

- Clinical Status
- Disease Activity (Time in Range, Complication Assessment)
- Hospitalization and appointment rate
- Disease prognosis
- Health literacy – disease knowledge
- Frequently asked questions
- Treatment adherence
- Patient behaviour (retention, satisfaction, engagement)

Evidence Generation

- Publications
 - Effect on QoL
 - Symptom Burden
 - Glycemic Control (HbA1c)
 - Adherence & Hospitalization
- White papers
- Expert Opinions
- Patient Characteristics

Anonymous Data Analysis


Aggregated Data for the customer



Why Digital Therapeutics?


DTx Is Now the Fastest-Growing Segment in Healthtech

Combined enterprise value of digital therapeutics startups has grown 8x since 2017, now totalling \$31B.




Still, DTx have relatively high growth in VC funding and low combined enterprise value compared to other healthtech segments.

VC funding growth 2022E vs. 2017



The Dtx market is projected to grow from \$5B today to \$32.5B in 2030 as it gradually finds a place in the healthcare ecosystem through the developments in regulation and reimbursement.

Global digital therapeutics market*



AH001 –Tele-rehabilitation

Evaluating Tele-rehabilitation Options During Post-operation Process of Knee Arthroplasty

Design: Interventional, Prospective, Three-armed Clinical Trial

Status: Active enrolment

Sites: Acibadem University



Aim

Investigate:
- Sync, async and face-to-face post-op rehabilitation effects on patient's knee functions



Condition - Population

- Adult patients who had knee surgery operations and signed a written consent will be included in the study.
- Estimated N: 40



Product Features

- Training videos
- Daily tasks
- Questionnaires after each exercise



Outcomes

Primary:
- Knee functions
- Muscle strength
- Pain assesment

Secondary:
- Knee scoring systems (PROMIS-29, IKDC)



AH002 – Heart Failure

AI-based Disease Management in the Vulnerable Period of Heart Failure (AIDMy-HF)

Design: Observational, Prospective, Two-armed Clinical Trial

Status: Active enrolment

Sites: Dokuz Eylul University, Karabuk University, Sivas Cumhuriyet University



Aim

Investigate:

- Relationship between heart failure symptoms, and vocal biomarkers during the hospitalization and post-discharge period
- Effect of post-discharge education on patient-reported outcomes and re-hospitalization.



Condition - Population

- Hospitalized adult patients admitted to the Cardiology Department due to heart failure decompensation and signed a written consent will be included in the study.
- Estimated N: 76



Product Features

- Identify changes in patients' voice during the hospitalization and post-discharge period
- Track heart failure symptoms
- Post-discharge education with HF-specific content



Outcomes

Primary:

- Heart failure-related hospitalizations
- Change from baseline in health-related quality of life

Secondary:

- Patient-reported outcomes



AH003 – MS

Tracking MS progression using MS+

Design: Observational, Prospective, Two-armed, Validation Study

Status: Ethics Approval

Sites: Sancaktepe Training and Research Hospital



Aim

Evaluate the usability of MS+ and define user characteristics
-Validation of mobile 2-6 minute walking test for clinical use of MS+ to track progression.



Condition - Population

- MS patients admitted to the Neurology Department with EDSS<4 and signed a written consent will be included in the study.
- Estimated N: 40



Product Features

- Mobile 2-6 minute walking test
- Tracking MS symptoms
- Education with MS-specific content
- Psychological and dietary support



Outcomes

Primary:
- 2-6 minute walking test validation
Secondary:
- Patient-reported outcomes(QoL)
- Usability



You Are Covered!

Local data storage



Health Authority Registration



Software Validation



Quality Certifications



Clinical Risk Management




DCB 0129
NHS CLINICAL RISK
MANAGEMENT STANDARD

albert



Digital health app sustainability & half-life is critical

The Release and Removal of Health Apps from Stores Over Time



Source: 42 Matters, Jun 2021 and Jul 2017; Mevvy, Jun 2015; IQVIA AppScript App Database, Jun 2021; IQVIA Institute, Jun 2021

Notes: Includes digital health apps that are publicly available to consumers and categorized as Health & Fitness or Medical.

Report: Digital Health Trends 2021: Innovation, Evidence, Regulation, and Adoption. IQVIA Institute for Human Data Science, July 2021



Example

Migraine Diary



AH004 – Growth Hormone Deficiency

Evaluation of treatment adherence of GHD patients using the Groconnect mobile application

Design: Observational, Prospective, Two-armed Clinical Trial

Status: Protocol Preparation

Sites: Ege University, Uludag University, Istanbul University - Cerrahpasa , other sites will be decided.



Aim

- Define adherence rates of newly diagnosed and old patients that taking GH therapy with a digital tool.
- Show the adherence decline of GH treatment during the study
- Show the decrease in growth rates with the decrease in adherence to treatment.
- Evaluate the effectiveness of Groconnect on treatment adherence and growth rates



Condition - Population

- Currently taking or new GH therapy patients diagnosed with Isolated GH deficiency, Turner Syndrome and SGA.-
- Estimated N: 400



Product Features

- Motivate and educate patients about the importance of treatment adherence to Growth Hormone
- Track treatment adherence rate
- Assist patients by reminding the injection site
- Psychological and dietary support



Outcomes

- Primary:
- Growth hormone treatment adherence rate
 - Growth rates
- Secondary:
- Patient-reported outcomes

